Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Effects of Bacille Calmette-Guerin after the first Demyelinating event in the CNS
Neurol 82:41-48, Ristori, G.,et al, 2014
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Brain Arteriovenous Malformation Multiplicity Predicts the Diagnosis of Hereditary Hemorrhagic Telangiectasia Quantitive Assessment
Stroke 43:72-78, Bharatha, A.,et al, 2012
HIV Screening of Male Inmates During Prison Intake Medical Evaluation - Washington, 2006-2010
JAMA 306:1756-1757, Strick, L.B., 2011
Impact of Late Diagnosis and Treatment on Life Expectancy in People with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
BMJ 343:d6016,d6015, May, M.,et al, 2011
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
The Neuroprotective Effects of Caffeine: A Prospective Population Study (the Three City Study)
Neurol 69:536-545, Ritchie,K.,et al, 2007
Premenstrual Multiple Sclerosis Pseudoexacerbations: Role of Body Temperature and Prevention With Aspirin
Arch Neurol 63:1005-1008, Wingerchuk,D.M. &Rodriguez,M., 2006
Behavioral Effects of Memantine in Alzheimer Disease Patients Receiving Donepezil Treatment
Neurol 67:57-63, Cummings,J.L.,et al, 2006
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004
Migraine
Lancet 363:381-391, Silberstein,S.D., 2004
Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 291:2947-2958,3005, Shumaker,S.A.,et al, 2004
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Leisure Activities and the Risk of Dementia in the Elderly
NEJM 348:2508-2516, Verghese,J.,et al, 2003
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Arch Neurol 60:940-946,923, Morris,M.C.,et al, 2003
Neurologic Manifestations and Outcome of West Nile Virus Infection
JAMA 290:511-515,524,558, Sejvar,J.J.,et al, 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women
JAMA 288:2123-2129,2170, Zandi,P.P.,et al, 2002
Hormone Replacement Therapy and Cognition
JAMA 285:1489-1499, LeBlanc,E.S.,et al, 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Immunization for Alzheimer's Disease: A Shot in the Arm or a Whiff?
Ann Neurol 48:553-555, Levey,A.I., 2000
Anti-Inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Arch Neurol 57:1586-1591, Broe,G.A.,et al, 2000
Rehabilitation of Persons With Traumatic Brain Injury
JAMA 282:974-983,989, NIH Consensus Development Panel on Rehab with TBI, 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Estrogen Therapy in Postmenopausal Women, Effects on Cognitive Function and Dementia
JAMA 279:688-695, Yaffe,K.,et al, 1998
Estrogen-replacement Therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
Neurol 50:996-1002, Baldereschi,M.,et al, 1998
Carbon Monoxide Poisoning
NEJM 339:1603-1608, Ernst,A. & Zibrak,J. D., 1998
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
Successful Treatment of Persistent Migraine Aura with Divalproex Sodium
Neurol 48:261-262, Rothrock,J.F., 1997
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
A Prospective Study of Estrogen Replacement Therapy and the Risk of Developing Alzheimer's Disease
Neurol 48:1517-1521, Kawas,C.,et al, 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997